@article{Long_M-2024_171621,
title = {SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial},
author = {Long, M. and Abo-Leyah, H. and Giam, Y. and Vadiveloo, T. and Hull, R. and Keir, H. and Pembridge, T. and De Lima, D. and Delgado, L. and Inglis, S. and Hughes, C. and Gilmour, A. and Gierlinski, M. and New, B. and MacLennan, G. and Dinkova-Kostova, A. and Chalmers, J.},
month = {jan},
year = {2024},
abstract = {Introduction Sulforaphane can induce the transcription factor, Nrf2, promoting antioxidant and anti-inflammatory responses. In this study, hospitalised patients with community-acquired pneumonia (CAP) were treated with stabilised synthetic sulforaphane (SFX-01) to evaluate impact on clinical status and inflammation.},
volume = {10},
issue = {2},
journal = {ERJ Open Research},
publisher = {ERS Publications},
url = {https://doi.org/10.1183/23120541.00917-2023},
}
